Reade Michael C, Bass Frances, Howe Belinda, Seppelt Ian, Shehabi Yahya
University of Queensland and Joint Health Command, Australian Defence Force, Brisbane, QLD, Australia.
Royal North Shore Hospital, Sydney, NSW, Australia.
Crit Care Resusc. 2017 Jun;19(2):110-114.
The Australian and New Zealand Intensive Care Society Clinical Trials Group and other investigator-led trials groups in critical care publish policies and guidelines outlining the rationale for considering co-enrolment in large, randomised controlled trials in intensive care medicine. However, none present a checklist of criteria by which a request for permission to co-enrol in an existing trial can be assessed. Consequently, such requests tend to be made and assessed on an ad hoc basis. Based on our experience in the SPICE III randomised controlled trial, we propose eight broadly applicable criteria (the SPICE-8 criteria) to be satisfied before co-enrolment should be approved. Reporting co-enrolment in trials, for regulatory purposes and in publications, is uncommon, partly because of the complexity involved in explaining a lack of a plausible coenrolment effect. We suggest that noting compliance with these criteria would simplify such reporting and enhance transparency.
澳大利亚和新西兰重症监护学会临床试验小组以及其他由研究者主导的重症监护试验小组发布了相关政策和指南,概述了在重症监护医学领域考虑共同纳入大型随机对照试验的基本原理。然而,没有一个小组提供一份标准清单,用以评估请求在现有试验中进行共同纳入的申请。因此,此类请求往往是临时提出并临时评估。基于我们在SPICE III随机对照试验中的经验,我们提出了八项广泛适用的标准(SPICE - 8标准),在批准共同纳入之前应满足这些标准。出于监管目的以及在出版物中报告试验中的共同纳入情况并不常见,部分原因在于解释缺乏合理的共同纳入效应所涉及的复杂性。我们建议记录对这些标准的遵守情况将简化此类报告并提高透明度。